Genetic toxicology in silico protocol

被引:52
作者
Hasselgren, Catrin [1 ]
Ahlberg, Ernst [2 ]
Akahori, Yumi [3 ]
Amberg, Alexander [4 ]
Anger, Lennart T. [4 ]
Atienzar, Franck [5 ,53 ]
Auerbach, Scott [6 ]
Beilke, Lisa [7 ]
Bellion, Phillip [8 ]
Benigni, Romualdo [9 ]
Bercu, Joel [10 ]
Booth, Ewan D. [11 ]
Bower, Dave [12 ]
Brigo, Alessandro [13 ]
Cammerer, Zoryana [14 ]
Cronin, Mark T. D. [15 ]
Crooks, Ian [16 ]
Cross, Kevin P. [12 ]
Custer, Laura [17 ]
Dobo, Krista [18 ]
Doktorova, Tatyana [19 ]
Faulkner, David [20 ]
Ford, Kevin A. [21 ]
Fortin, Marie C. [22 ,23 ]
Frericks, Markus [24 ]
Gad-McDonald, Samantha E. [25 ]
Gellatly, Nichola [26 ]
Gerets, Helga [5 ]
Gervais, Veronique [27 ]
Glowienke, Susanne [28 ]
Van Gompel, Jacky [29 ]
Harvey, James S. [30 ]
Hillegass, Jedd [17 ]
Honma, Masamitsu [31 ]
Hsieh, Jui-Hua [32 ]
Hsu, Chia-Wen [33 ]
Barton-Maclaren, Tara S. [34 ]
Johnson, Candice [12 ]
Jolly, Robert [35 ]
Jones, David [36 ]
Kemper, Ray [37 ]
Kenyon, Michelle O. [18 ]
Kruhlak, Naomi L. [33 ]
Kulkarni, Sunil A. [34 ]
Kuemmerer, Klaus [38 ]
Leavitt, Penny [17 ]
Masten, Scott [6 ]
Miller, Scott [12 ]
Moudgal, Chandrika [1 ]
Muster, Wolfgang [13 ]
机构
[1] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA
[2] AstraZeneca IMED Biotech Unit, Drug Safety & Metab, Predict Compound ADME & Safety, Molndal, Sweden
[3] Chem Evaluat & Res Inst, Bunkyo Ku, 1-4-25 Kouraku, Tokyo 1120004, Japan
[4] Sanofi, R&D Preclin Safety Frankfurt, Ind Pk Hoechst, D-65926 Frankfurt, Germany
[5] UCB BioPharma SPRL, Chemin Foriest, B-1420 Braine Lalleud, Belgium
[6] NIEHS, Div Natl Toxicol Program, Res Triangle Pk, NC 27709 USA
[7] Toxicol Solut Inc, San Diego, CA USA
[8] DSM Nutr Prod, Kaiseraugst, Switzerland
[9] Alpha PreTox, Via G Pascoli 1, I-00184 Rome, Italy
[10] Gilead Sci, 333 Lakeside Dr, Foster City, CA USA
[11] Syngenta, Prod Safety Dept, Jealotts Hill Int Res Ctr, Bracknell RG42 6EY, Berks, England
[12] Leadscope Inc, 1393 Dublin Rd, Columbus, OH 43215 USA
[13] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharmaceut Res & Early Dev Pharmaceut Sci, Grenzacherstr 124, CH-4070 Basel, Switzerland
[14] Janssen Res & Dev, 1400 McKean Rd, Spring House, PA 19477 USA
[15] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool L3 3AF, Merseyside, England
[16] British Amer Tobacco, Res & Dev, Regents Pk Rd, Southampton SO15 8TL, Hants, England
[17] Bristol Myers Squibb, Drug Safety Evaluat, 1 Squibb Dr, New Brunswick, NJ 08903 USA
[18] Pfizer Global Res & Dev, 558 Eastern Point Rd, Groton, CT 06340 USA
[19] Douglas Connect GmbH, Technol Pk Basel,Hochbergerstr 60C, CH-4057 Basel, Switzerland
[20] Lawrence Berkeley Natl Lab, One Cyclotron Rd,MS 70A-1161A, Berkeley, CA USA
[21] Global Blood Therapeut, 171 Oyster Point Blvd, San Francisco, CA 94080 USA
[22] Jazz Pharmaceut Inc, 200 Princeton South Corp Ctr,Suite 180, Ewing, NJ 08628 USA
[23] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, 170 Frelinghuysen Rd, Piscataway, NJ 08855 USA
[24] BASF SE, D-67056 Ludwigshafen, Germany
[25] Gad Consulting Serv, 4008 Barrett Dr,Suite 201, Raleigh, NC 27609 USA
[26] Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England
[27] Servier Grp, 905 Route Saran, F-45520 Gidy, France
[28] Novartis Pharma AG, Preclin Safety, Werk Klybeck, CH-4057 Basel, Switzerland
[29] Johnson & Johnson, Janssen Pharmaceut Co, B-2340 Beerse, Belgium
[30] GlaxoSmithKline, Preclin Dev, Pk Rd, Ware SG12 0DP, Herts, England
[31] Natl Inst Hlth Sci, Div Genet & Mutagenesis, Kawasaki, Kanagawa 2109501, Japan
[32] Kelly Govt Solut, Res Triangle Pk, NC 27709 USA
[33] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[34] Hlth Canada, Existing Subst Risk Assessment Bur, Ottawa, ON K1A 0K9, Canada
[35] Eli Lilly & Co, Toxicol Div, Indianapolis, IN 46285 USA
[36] Med & Healthcare Prod Regulatory Agcy, 10 South Colonnade, London E14 4PU, England
[37] Vertex Pharmaceut Inc, Predict & Invest Safety Assessment, 50 Northern Ave, Boston, MA USA
[38] Leuphana Univ Luneburg, Inst Sustainable & Environm Chem, Scharnhorststr 1-C13-311b, D-21335 Luneburg, Germany
[39] Oro Agri Setubal, Palmela, Portugal
[40] Nestle Res Vers Chez Les Blanc, Lausanne, Switzerland
[41] Merck Res Labs, West Point, PA 19486 USA
[42] European Commiss, Joint Res Ctr, Ispra, Italy
[43] RDS Consulting Serv, 2936 Wooded Vista Ct, Mason, OH 45040 USA
[44] Safetree Consulting eU, Vienna, Austria
[45] PPG Ind Inc, Pittsburgh, PA 15146 USA
[46] AstraZeneca, Macclesfield, Cheshire, England
[47] RTice Consulting, Hillsborough, NC USA
[48] Colgate Palmol Co, Piscataway, NJ 08854 USA
[49] Bibra, Railway Approach, Cantium House, Wallington SM6 0DZ, Surrey, England
[50] Bayer AG, Invest Toxicol, Pharmaceut Div, Muellerstr 178, D-13353 Berlin, Germany
基金
美国国家卫生研究院;
关键词
In silico; In silico toxicology; Computational toxicology protocols; (Q)SAR; Expert alerts; Expert review; Genetic toxicology; GENOTOXICITY TESTING IWGT; CHEMICAL RELATIONAL DATABASES; THROUGHPUT SCREENING APPROACH; INTERNATIONAL WORKSHOP; MAJOR CONCLUSIONS; ENVIRONMENTAL CHEMICALS; MUTATION ASSAY; MECHANISMS; DAMAGE; VITRO;
D O I
10.1016/j.yrtph.2019.104403
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
In silico toxicology (IST) approaches to rapidly assess chemical hazard, and usage of such methods is increasing in all applications but especially for regulatory submissions, such as for assessing chemicals under REACH as well as the ICH M7 guideline for drug impurities. There are a number of obstacles to performing an IST assessment, including uncertainty in how such an assessment and associated expert review should be performed or what is fit for purpose, as well as a lack of confidence that the results will be accepted by colleagues, collaborators and regulatory authorities. To address this, a project to develop a series of IST protocols for different hazard endpoints has been initiated and this paper describes the genetic toxicity in silico (GIST) protocol. The protocol outlines a hazard assessment framework including key effects/mechanisms and their relationships to endpoints such as gene mutation and clastogenicity. IST models and data are reviewed that support the assessment of these effects/mechanisms along with defined approaches for combining the information and evaluating the confidence in the assessment. This protocol has been developed through a consortium of toxicologists, computational scientists, and regulatory scientists across several industries to support the implementation and acceptance of in silico approaches.
引用
收藏
页数:21
相关论文
共 120 条
[1]   Guidance on the establishment of the residue definition for dietary risk assessment [J].
Adriaanse, Paulien ;
Brock, Theodorus ;
Berny, Philippe ;
Duquesne, Sabine ;
Grilli, Sandro ;
Hernandez-Jerez, Antonio F. ;
Bennekou, Susanne Hougaard ;
Klein, Michael ;
Kuhl, Thomas ;
Laskowski, Ryszard ;
Machera, Kyriaki ;
Ockleford, Colin ;
Pelkonen, Olavi ;
Pieper, Silvia ;
Smith, Rob ;
Stemmer, Michael ;
Sundh, Ingvar ;
Teodorovic, Ivana ;
Aaldrik, Tiktak ;
Topping, Chris J. ;
Wolterink, Gerrit .
EFSA JOURNAL, 2016, 14 (12)
[2]   Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity [J].
Ahlberg, Ernst ;
Amberg, Alexander ;
Beilke, Lisa D. ;
Bower, David ;
Cross, Kevin P. ;
Custer, Laura ;
Ford, Kevin A. ;
Van Gompel, Jacky ;
Harvey, James ;
Honma, Masamitsu ;
Jolly, Robert ;
Joossens, Elisabeth ;
Kemper, Raymond A. ;
Kenyon, Michelle ;
Kruhlak, Naomi ;
Kuhnke, Lara ;
Leavitt, Penny ;
Naven, Russell ;
Neilan, Claire ;
Quigley, Donald P. ;
Shuey, Dana ;
Spirkl, Hans-Peter ;
Stavitskaya, Lidiya ;
Teasdale, Andrew ;
White, Angela ;
Wichard, Joerg ;
Zwickl, Craig ;
Myatt, Glenn J. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2016, 77 :1-12
[3]   Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses [J].
Amberg, Alexander ;
Beilke, Lisa ;
Bercu, Joel ;
Bower, Dave ;
Brigo, Alessandro ;
Cross, Kevin P. ;
Custer, Laura ;
Dobo, Krista ;
Dowdy, Eric ;
Ford, Kevin A. ;
Glowienke, Susanne ;
Van Gompel, Jacky ;
Harvey, James ;
Hasselgren, Catrin ;
Honma, Masamitsu ;
Jolly, Robert ;
Kemper, Raymond ;
Kenyon, Michelle ;
Kruhlak, Naomi ;
Leavitt, Penny ;
Miller, Scott ;
Muster, Wolfgang ;
Nicolette, John ;
Plaper, Andreja ;
Powley, Mark ;
Quigley, Donald P. ;
Reddy, M. Vijayaraj ;
Spirkl, Hans-Peter ;
Stavitskaya, Lidiya ;
Teasdale, Andrew ;
Weiner, Sandy ;
Welch, Dennie S. ;
White, Angela ;
Wichard, Joerg ;
Myatt, Glenn J. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2016, 77 :13-24
[4]   Do Carboxylic/Sulfonic Acid Halides Really Present a Mutagenic and Carcinogenic Risk as Impurities in Final Drug Products? [J].
Amberg, Alexander ;
Harvey, James S. ;
Czich, Andreas ;
Spirkl, Hans-Peter ;
Robinson, Sharon ;
White, Angela ;
Elder, David P. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2015, 19 (11) :1495-1506
[5]  
[Anonymous], FLAV EXTR MAN ASS US
[6]  
[Anonymous], TEST 483 MAMM SPERM, DOI DOI 10.1787/9789264264847-EN
[7]  
[Anonymous], GUID INF REQ CHEM SA
[8]  
[Anonymous], 2016, TEST 476 IN VITR MAM, DOI DOI 10.1787/9789264264809-EN
[9]  
[Anonymous], S2 R1 GEN TEST DAT I
[10]  
[Anonymous], OECD SER TEST ASS